Leading International Investment Research

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Leading International Investment Research, Edison Investment Research

Equity Bottom-Up

Newron Pharmaceuticals / Equity Bottom-Up

<p>Newron is developing evenamide as an add-on to existing anti-psychotic therapies to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase II/III study is starting in Europe, Asia and Latin America. This could report by Q422. It uses an intended therapeutic dose of 30mg twice per day. We maintain our indicative value of CHF121m.</p>

Newron is developing evenamide as an add-on to existing anti-psychotic therapies to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase II/III study is starting in Europe, Asia and Latin America. This could report by Q422. It uses an intended therapeutic dose of 30mg twice per day. We maintain our indicative value of CHF121m.

Newron Pharmaceuticals - Evenamide Phase III at 30mg twice daily dose